UCLA scientists use stem cells to study genetics of germ cell tumors

UCLA researchers have made new inroads into understanding germ cell tumors, a diverse and rare group of cancers that begin in germ cells — the cells that develop into sperm and eggs. The researchers developed a protocol to recreate germ cell tumor cells from stem cells and used the new model to study the genetics of the cancer.Their findings could point the way toward new drugs to treat germ cell tumors, which account for around 3 percent of all cases of childhood and adolescent cancer.The study, published in Stem Cell Research, was led by Amander Clark, a UCLA professor of molecular cell and developmental biology and a member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.Germ cell tumors most often develop during embryonic development, in the testes and ovaries, but they can also occur in the spine, chest and brain when germ cells mistakenly migrate there.UCLA Broad Stem Cell Research Center/ElsevierEmbryonal carcinoma cells expressing the PRDM14 proteinThere are five subtypes of germ cell tumors: germinomas, embryonal carcinomas, yolk sac tumors, choriocarcinomas and teratomas. Each has its own unique properties, but most of them affect young children, adolescents and young adults.“What makes this cancer really hard to study is that we think the disease begins in the womb and then remains latent until after birth or during young adulthood,” Clark said. “That means we can’t easily isolate or study the ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

CONCLUSION: This is the first case to our knowledge describing both such lesions in one patient and the first case describing the use of 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL)-PSMA PET/CT to detect IPAS. Furthermore we highlight the value of nuclear medicine diagnostic work up in complex cases. PMID: 30006647 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
CONCLUSION: Our results from this totally original study indicated that radioactive isotope 125I labeled to caerin peptide 1.9 may be used to treat breast cancer while at the same time the response to treatment may be monitored by simultaneous imaging. PMID: 30006645 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
CONCLUSION: A method of tumor size determination, using PHL on 18F-FDG PET/CT, showed more linear relationship and smaller size differences with pathology than MRI (average 0.6 vs. 1.9cm). It provides sufficient reliability and reproducibility for measuring tumor size in breast cancer. PMID: 30006644 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
Abstract Breast-conserving surgery (BCS) followed by radiation therapy is the current standard of care for early stage breast cancer. Successful BCS necessitates complete tumor resection with clear margins at the pathologic assessment of the specimen ("no ink on tumor"). The presence of positive margins warrants additional surgery to obtain negative final margins, which has significant physical, psychological, and financial implications for the patient. The challenge lies in developing accurate real-time intraoperative margin assessment techniques to minimize the presence of "ink on tumor" and ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
Management of the Axilla in the Patient with Breast Cancer. Surg Clin North Am. 2018 Aug;98(4):747-760 Authors: Park KU, Caudle A Abstract Evaluation of the axillary lymph nodes is critical in the management of breast cancer because it is a key predictor of survival outcome. Surgeons must not only be able to perform sentinel lymph node dissection with high accuracy but also understand the implications of the results. Management of clinically node-negative and node-positive cases can vary significantly, as described in this review. With emerging data, management of the axilla in breast cancer will...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
Abstract Ductal carcinoma in situ has been stable in incidence for a decade and has an excellent prognosis. Breast conservation therapy is safe and effective for most patients. Adjuvant whole breast radiation therapy is recommended to reduce the risk of local recurrence. Accelerated partial breast irradiation is a promising alternative to decrease toxicity and improve cosmetic results. Adjuvant hormonal therapy can reduce local recurrence, but should be used cautiously. Future directions in management include developing predictive tools for guidance for use of adjuvant therapy and selecting low-risk patients ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
Abstract New emerging breast imaging techniques have shown great promise in breast cancer screening, evaluation of extent of disease, and response to neoadjuvant therapy. Tomosynthesis, allows 3-dimensional imaging of the breast, and increases breast cancer detection. Fast abbreviated MRI has reduced time and costs associated with traditional breast MRI while maintaining cancer detection. Diffusion-weighted imaging is a functional MRI technique that does not require contrast and has shown potential in screening, lesion characterization and also evaluation of treatment response. New image-guided preoperative locali...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
Abstract The American Joint Committee on Cancer staging system has evolved in response to improved imaging, refined surgical techniques, enhanced pathologic evaluation, and greater understanding of tumor biology. The 8th edition has introduced clinical and pathologic prognostic stages for breast cancer that incorporate biologic variables (grade, estrogen/progesterone receptor status, HER2 status, multigene panels) with TNM categories that define the anatomic stage. The prognostic staging system facilitates more refined stratification than the anatomic stage with respect to survival and is an important advance that...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
Abstract As more genetic information becomes available to inform breast cancer treatment, screening, and risk-reduction approaches, clinicians must become more knowledgeable about possible genetic testing and prevention strategies, including outcomes, benefits, risks, and limitations. The aim of this article is to define and distinguish high- and moderate-risk breast cancer predisposition genes, summarize the clinical recommendations that may be considered based on the identification of pathogenic variants (mutations) in these genes, and indications for risk-reducing and contralateral prophylactic mastectomy. ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
PMID: 30005782 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
More News: Biology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Carcinoma | Cardiology | Career Development | Chemotherapy | Child Development | Childhood Cancer | Children | Choriocarcinoma | Cytology | Embryonal Carcinoma | Genetics | Germ Cell Tumors | Girls | Grants | Heart | Heart Disease | Infertility | Molecular Biology | Neurology | Ovarian Cancer | Ovaries | Pathology | Pediatrics | Reproduction Medicine | Seminoma | Skin | Stem Cell Therapy | Stem Cells | Study | Teratoma | Testicular Cancer | Training | Universities & Medical Training | Yolk Sac Tumor